Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Published:2017-02-15 Issue:8 Volume:77 Page:2078-2089
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Nukaga Shigenari,Yasuda Hiroyuki,Tsuchihara Katsuya,Hamamoto Junko,Masuzawa Keita,Kawada Ichiro,Naoki Katsuhiko,Matsumoto Shingo,Mimaki Sachiyo,Ikemura Shinnosuke,Goto Koichi,Betsuyaku Tomoko,Soejima Kenzo

Funder

Ministry of Education, Culture, Sports, Science and Technology

Japan Agency for Medical Research and Development

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-HDGF Antibody Targets EGFR Tyrosine Kinase Inhibitor–Tolerant Cells in NSCLC Patient-Derived Xenografts;Cancer Research Communications;2024-09-01

2. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer;European Journal of Cancer;2024-09

3. Design and activity evaluation of new EGFR tyrosine kinase inhibitors containing cyclic polyamines;Bioorganic & Medicinal Chemistry Letters;2024-09

4. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

5. The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma;Pathology - Research and Practice;2024-07